Also known as: Arcellx
Arcellx is a biotechnology company focused on engineering cell therapies designed to be safer, more effective, and more accessible. Its platform and pipeline include CAR-T programs such as anitocabtagene autoleucel.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
The global oncology market is projected to nearly triple from $279.98 billion in 2026 to $748.17 billion by 2035, driven by rapid adoption of immunotherapy, checkpoint inhibitors, and cell therapies across solid tumors and hematologic cancers.
The pharmaceutical industry is experiencing recovery driven by innovation in drug development, aggressive M&A activity, and expansion of drug development services. The sector faces both opportunities and headwinds including pipeline setbacks and regulatory pressures.
Gilead Sciences has agreed to buy immunotherapy cancer biotech Arcellx in a deal worth $7.8 billion, deepening its bet on cancer immunotherapy and its existing partnership with the company.
Gilead Sciences will acquire Arcellx for $7.8 billion to expand their CAR-T cell therapy collaboration. The deal includes $115 per share at closing plus contingent payments based on sales milestones.
Eli Lilly launched the monthly Zepbound KwikPen for obesity treatment and initiated a Phase 2 trial for opioid use disorder, while Gilead Sciences agreed to acquire Arcellx for $7.8 billion to expand its cell therapy portfolio.
Gilead Sciences entered a definitive agreement to acquire Arcellx for $115 per share in cash plus a $5 contingent value right, representing an implied equity value of $7.8 billion. The acquisition provides Gilead with full control of anito-cel, an investigational BCMA-directed CAR T-cell therapy for multiple myeloma.
